New eye drug trial aims to slow vision loss from geographic atrophy
NCT ID NCT07230834
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This early-stage study tests an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy (GA) — a condition where parts of the retina stop working, leading to vision loss. The main goal is to check the drug's safety and tolerability in 54 participants. Researchers will also measure how much drug stays in the body and whether the immune system reacts to it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY (GA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ARENSIA Clinics SRL
RECRUITINGBucharest, 011658, Romania
-
Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca
RECRUITINGCluj-Napoca, 400006, Romania
-
Arensia Exploratory Medicine at the Research Institute of Clinical Medicine
RECRUITINGTbilisi, 0112, Georgia
-
Austin Retina Associates
RECRUITINGAustin, Texas, 78705, United States
-
Colorado Retina Associates
RECRUITINGLakewood, Colorado, 80228, United States
-
Emanuelli Research and Development Center
RECRUITINGArecibo, 00612, Puerto Rico
-
Ophthalmic Consultants of Boston
RECRUITINGEast Weymouth, Massachusetts, 02189, United States
-
Retina Consultants Texas
RECRUITINGThe Woodlands, Texas, 77384, United States
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.